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Abstract
Study Design: Literature Review (Narrative).
Objective: To contextualize AO Spine RECODE-DCM research priority number 5: What is the socio-economic impact of
DCM? (The financial impact of living with DCM to the individual, their supporters, and society as a whole).
Methods: In this review, we introduce the methodology of health-economic investigation, including potential techniques and
approaches. We summarize the current health-economic evidence within DCM, so far focused on surgical treatment. We also
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cover the first national estimate, in partnership with Myelopathy.org from the United Kingdom, of the cost of DCM to society.
We then demonstrate the significance of this question to advancing care and outcomes in the field.
Results: DCM is a common and often disabling condition, with a significant lack of recognition. While evidence demonstrates the
cost-effectives of surgery, even among higher income countries, health inequalities exist. Further the prevalent residual disability
in myelopathy, despite treatment affects both the individual and society as a whole. A report from the United Kingdom provides
the first cost-estimate to their society; an annual cost of *£681.6 million per year, but this is likely a significant underestimate.
Conclusion: A clear quantification of the impact of DCM is needed to raise the profile of a common and disabling condition.
Current evidence suggests this is likely to be globally substantial.
Keywords
cervical myelopathy, cervical spondylosis, cervical stenosis, disc herniation, ossification posterior longitudinal ligament, degeneration, research priorities, health economics, socioeconomics, policy

Introduction
Degenerative Cervical Myelopathy [DCM] is a neurological
disorder arising from degenerative, arthritic, and/or congenital processes, causing cervical spinal cord dysfunction.1,2
DCM can result in a wide range of impairments and disabilities, including poor balance, limited mobility, loss of dexterity, sensory loss, bowel or bladder dysfunction, pain and in
severe cases, paralysis.1 DCM is estimated to affect and contribute to neurologic dysfunction in up to 2% of the adult
population.3 Given the increased prevalence of spinal degeneration with age, the incidence of DCM is expected to rise as
populations age.4
Currently surgical decompression is the only evidencebased treatment recommended for progressive or moderate
to severe disease.5 For most patients surgical intervention can
halt disease progression and afford some meaningful recovery. However, recovery is normally incomplete, with some
deficits and leaving individuals with life-long disabilities,
dependency, unemployment, and mental health difficulties.6,7
In a comparison of SF-36 [the Short Form—(36) Health Survey of Quality of Life) scores of people with chronic disease,
individuals with DCM were found to have the lowest quality
of life scores.7 Moreover, the impact is not restricted to the
individual, with a quality of life burden demonstrated among
their family and/or acquaintance carers.8 Therefore, efforts to
address and improve DCM outcomes should be a critical public health priority.
AO Spine RECODE-DCM (aospine.org/recode) [REsearch
objectives and COmmon Data Elements for DCM] is an international consensus project which aims to accelerate knowledge
discovery that can improve outcomes by developing a set of
research tools.9 These include a James Lind Alliance research
priority setting partnership, which brought together both individuals living and working with DCM to establish the most
important unanswered questions. Research prioritization aims
to catalyze progress by consolidating resources on key knowledge gaps.10 The Number 8 priority identified was to establish
the socio-economic impact of DCM. The term socio-economic
impact was used here to encompass the health-economic
impact on the individual and society.

This article aims to contextualize: (a) the significance of this
question; (b) to explain what is meant by socio-economic
impact and how it can be measured; (c) to summarize the
current evidence from within DCM and to provide a current
best estimate, and (d) illustrate why this is a critical knowledge
gap for the field that needs to be overcome to help improve
outcomes.

What Is Meant by Socio-Economic Impact, and How
Can It Be Measured?
In this priority, the wording “socio-economic impact” was used
to represent both the health-economic impact to the individual
and to society. Health economics is the application of economic
theory, decision-making models, and empirical techniques to
analyze and make decisions on health and healthcare by taking
into consideration the available resources as well as the values
and needs from different stakeholders including individuals,
health care providers, and governments.11 Simply stated, the
aim of health technology assessment is to provide techniques to
help manage limited resources most efficiently to achieve the
best outcomes in populations.
There are several techniques that can be used largely
depending on the perspective of the intended audience and
the availability of data.12 When developing assessments, it
is important to include the costs that are particularly relevant
to the audience. For example, patients are most interested in
the outcomes of the treatment and may have little or no interest in the cost of providing it (unless they are directly paying
for it); the provider, however, wants satisfied patients but,
more importantly, needs to be able to provide the treatment
as cost-efficiently as possible, which means achieving the
maximum benefit using the least resources (including money,
time and manpower). Finally, the external payer (i.e. governments or private healthcare insurance) is looking for the
most efficient means of providing a range of effective treatments within a limited budget. In summary, when undertaking health economic analysis, only those costs and/or
benefits that are relevant to the particular audience or purpose
should be included.
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Figure 1. Summary of types of health economic analysis, including their
principal purpose (represented as Output) and data requirements
(represented as Input).

Taking each audience in turn, the primary data needs are:
Patient:
Provider:

Payer:

clinical benefits, safety, and quality of life.
Incidence, cost of managing the condition: cost
of surgery, resource usage (bed stay, outpatient,
and other visits).
as with the provider but also additional direct
costs such as absenteeism, lost production, disability benefits, and tax lost due to the condition.

In terms of the “how to measure the socioeconomic impact,”
this depends on the purpose of the analysis and, more importantly, how generalizable the results need to be (Figure 1). The
commonly used methods include:
Cost analysis. This is a basic assessment of the costs of managing
a condition without any consideration of the outcomes. The
result cannot be used to compare with other treatments for the
same condition, nor across treatments.
Cost minimization analysis. This is the simplest form of comparative analysis where the same outcome is possible using different treatments. In this context, the least costly treatment is
deemed the most cost effective. For example, different antibiotics being used to treat a chest infection or, in the case of DCM,
it might be a comparison of different surgical techniques where
the same outcome will be achieved but at different costs of
surgery.
Cost effectiveness analysis (CEA). This is a method to compare
both the costs and health outcomes of one or more interventions
by estimating how much it costs to gain a health outcome unit
like a life year gained or a death prevented.
Cost utility analysis (CUA). The aim of a CUA is to attach a
monetary value to outcomes to allow comparison across conditions. The most frequent common denominator is the Quality
Adjusted Life Year (QALY), a generic measure of disease
burden, which includes both the quality and quantity of life.
Quality of life can be assessed in a variety of ways such as:
Time Trade Off where an individual is asked to choose between
remaining in a state of ill health for a period of time or being
restored to perfect health but having a shorter life expectancy. The

point where the respondent switch sides corresponds to the utility
value for that health state.
Standard gamble where an individual is asked to choose
between remaining in a state of ill health for a period of time or
choosing a medical intervention that has a chance of either restoring them to perfect health or killing them. The point where the
respondent changes opinion is considered the utility value for that
health state.
Visual Analogue Scale where respondents are asked to rate a
state of ill health on a scale from 0 to 100, with 0 representing
being dead and 100 representing perfect health.

A generic scale which can be used in any condition that
gives a weight associated with a particular health state is to
use standard descriptive systems such as the EuroQol Group’s
EQ-5D questionnaire, which categorizes health states according to 5 dimensions: mobility, self-care, usual activities (e.g.,
work, study, homework or leisure activities), pain/discomfort
and anxiety/depression. While the SF-36 is the most commonly
used quality of life score in DCM research today,13,14 for health
economic analysis it must be mapped to the SF6D healthy
utility.15,16
The result is a calculated index that ranges from 1 (perfect
health) to 0 (dead); so one QALY equates to 1 year in perfect
health. By associating the effect of treatment on quality of life
and applying the cost of getting there, the cost/QALY can be
estimated.
Several authorities use the Incremental Cost Effectiveness
Ratio (ICER) to determine the value of new treatments. The
ICER can be defined as:
cost of new treatment  cost of standard treatment
QALY of new treatment  QALY of standard treatment
For example, in England, the National Institute for Health
and Care Excellence (NICE) uses a threshold of £20 000 to
determine whether a new treatment should be introduced for
use in the NHS.17 There are some exceptions to this threshold,
for example, in certain cancers, rare diseases, or where patients
have limited life expectancy. These thresholds are therefore
influenced by a number of factors and are typically set per
healthcare system:18 the World Health Organisation recommends using a threshold based on Gross Domestic Product to
personalize recommendations.19

What Is the Current Health-Economic Evidence
Within DCM, and Why Must This Improve?
Within DCM, the health-economic evaluation has been
restricted to evaluations of treatment cost, in particular surgery.20-23 Across the board, these studies strongly confirm the
overall cost-effectiveness of surgery.21 Moreover, as a single
up-front relatively high cost, with benefit likely extended well
beyond the follow-up period, the study by Witiw et al (2016)
using a Markov transitional model to estimate a life-time benefit is a high-quality example. This study, using a Canadian
cohort of 171 patients, demonstrated cost-effectiveness, as per
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the World Health Organization criteria, in 94.7% of estimates.20 Further examples of health economic comparisons
between surgical techniques, 24 and surgery versus nonoperative management have also been conducted22 but are
more limited based on the quality of reference data.18
While robust health-economic evidence is necessary to support the adoption of clinical treatments, particularly within
single payer healthcare systems, these evaluations do not serve
to fully characterize the complete burden of illness; for example, the cost at a societal level or for the individual. These are
likely more fundamental to driving system-wide changes,
including healthcare policy, social care policy, and increased
research investment, fundamental to future healthcare gains in
DCM. Moreover, the cost to an individual is often an important
determinant of quality of life, and mental well-being, for which
the burden is well demonstrated, but the drivers are not.7
However, to calculate the cost of illness, several key pieces
of evidence are required:
1.
2.
3.
4.
5.

How many people are affected?
At what age does the condition develop?
What are the direct costs of managing the condition?
What are the indirect costs of managing the condition?
What are the costs to the individual, their caregivers,
healthcare providers, payer, and society at large?

Unfortunately, most of these questions are poorly defined
in DCM.

What Is a Current Best Estimate Within DCM?
Myelopathy.org (Cambridge, United Kingdom) is the first, and
so far, only, charity dedicated to DCM. Launched in 2018, it
hosts a growing and international community of individuals
living with DCM but also working with DCM.25 Fundamentally it aims to increase awareness and improve outcomes for
those living with the condition. As part of these objectives, it
has recently commissioned the first dedicated report on the
burden of illness in DCM. The report made use of the best
available data within the UK.
The prevalence of DCM was estimated based on International Classification of Disease (ICD-10) codes M47.12,
M50.0, M99.31/.41/.51 from the National Health Service hospital episode statistics data, from inception (2013) to the end of
2019. This dataset provides overall event data for England
(including wait time, and primary and secondary ICD codes),
and some demographic data (age and gender). Extrapolating
this across the UK population gave an estimated incidence of
7.44/100,00 (+0.32), in keeping with the literature.
Age of presentation was calculated by combining mean hospital waiting times from the hospital episode statistics data
(73.6 days) with time to diagnosis data (assumed to be a surrogate for data of referral) from the literature; 2 retrospective
cohort studies with average waits of 1.25 to 2.2 years.6,26 This
was then subtracted from the average age at presentation
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(62.1 years overall, or 51.3 years for those of working age,
defined as 18 to 65 years) to estimate the average age at which
patients have sufficiently severe symptoms to seek medical
intervention in the UK (i.e. 59.9 years overall or 49.1 years for
those of working age).
Healthcare treatment costs were also extracted from the UK
National Health Service Database for the aforementioned
cases. For the most recent year queried (2018-2019), the
total cost of care for DCM in England was estimated to be
£38 871 534; £9216 weighted average per hospital admission.
Productivity is typically calculated up to the age of retirement as it is assumed that once a person reaches retirement age,
they are no longer considered to be contributing members of
society. This is not the case for many older people as they may
provide voluntary work or non-paid family support such as
looking after grandchildren so that their parents can go out to
work, but it is more difficult to assess the value of this. Furthermore, several elderly individuals continue working beyond the
age of 65 years old either for their choice or need due to
financial burden. Based on the average age of these cases at
presentation, and an average age of retirement of 65, this equated to a potential 15.1 years of affected productivity. In a previous survey conducted by Myelopathy.org6 of those under the
age of 65 (N ¼ 537), 41% were unable to work due to their
disability, 28% were employed full time, 14% employed parttime, and 7% retired.
To estimate lost personal income in the UK, this data was
further restricted to UK respondents 18 to 65 (N ¼ 199), looking for work (45%). In the absence of linked income data,
average weekly income for the UK population was taken from
the UK Office for National Statistics (ONS) [£511/week working full time and £139.52/week working part-time (based on
the average part time employment of 16 hrs per week)] and
Office for Economic Co-Operation (OECD).27,28 Assuming
an average individual works 48 weeks per year, this equates
to a potential loss of income through unemployment of £18 663
(ONS data) or £25 524 (OECD data). Therefore, assuming a 3%
inflation rate (a standard assumption for health technology
assessments), and a loss of productivity of 15.1 years, the lifetime inflated loss of income could be £347 112 using ONS
figures or £474 719 using OECD values. Considering disability
benefits, and using the UK ‘Universal Credit’ allowance for a
single person, aged over 25, with limited capacity to work, of
£9021.72/year, this would equate to a £9641 (51%) or £16 503
(65%) reduction in personal income. Based on the average age
of the UK population in 2019 of 81.2, disability benefits on
average would be claimed for 16.5 years in those age >65 years
and 30.5 years in those hospitalized with DCM at the average
age of 51.1 years (13.9þ16.5).
Based on these compiled best estimates, the following data
can be integrated to yield an estimated (rounded to nearest
£100 000) annual loss of productivity of £362.6m, disability
benefits of £280.2m and therefore overall cost to society for
this cohort of £681.6m (Figure 2).
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Figure 2. Estimate of overall annual cost to society, United Kingdom
(myelopathy.org, United Kingdom). Total costs are round to nearest
£100 000. In 2018, there were 4218 admissions, at an average cost of
£9216 per admission: total cost of admission £38 900 000. Of these
admissions, 2264 were within working age (defined as between 18 and
65), with an average 15.1 years remaining before retirement. Based on
Pope et al6 up to 45% (1019) could be unable to return to work. The
weighted annual average salary for 2018 is £25 524. For those of
working age, lifetime loss of productivity is £362.6m. The weighted
average disability payment (2020) is £9021.72, which based on 16.5
years of life remaining for those of >65 years and 30.5 years
(13.9þ16.5) in those hospitalized with DCM at the average age of 51.1
years, gives a total annual cost of £280.2m.

How Accurate Is This Estimate?
These calculations are based upon the best available data today.
However, the calculations have their intrinsic limitations,
including reliance on integrating aggregate data from different
sources. While this, therefore, represents our best and only
estimate so far, these data are likely to change. In terms of
whether the estimate is under or over, there is much to suggest
that these figures could increase substantially.
One of the challenges for population-level research in DCM
is case ascertainment: today, there isn’t a specific ICD code for
DCM.29,30 Instead, studies must select from various codes
which can only approximate to varying degrees of specificity.
The aforementioned report took a conservative approach to
case identification using 4 codes, whereas many other studies
have used additional codes, for example, in a population analysis for degenerative spinal conditions in Finland.31 For this
reason, but also driven by recognized underdiagnosis, the true
incidence, and prevalence of DCM is unknown. A recent metaanalysis of MRI cervical spine imaging in healthy cohorts
identified a point prevalence of undiagnosed DCM of 2.4%.3
While this will likely include much milder disability (less
likely to require surgery, more likely to be employed), this
would undoubtedly increase the economic estimates for DCM
on population numbers alone. AO Spine RECODE-DCM9 is
seeking to establish consensus for an index term, to propose a
unifying ICD code.
Furthermore, the hospital events data are unlikely to capture
the complete cost of care; for example, data does not include
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primary care, while care within other specialties for subsequent
disabilities such as pain, mental health, urology are not
captured.
Traumatic spinal cord injury has more clearly defined the
full economic impact of disease, benefiting from clear disease
classification and within the UK, life-long follow up by Spinal
Rehabilitation Services. This dataset has recently enabled an
estimated lifetime cost of £1.43 billion based on current incidence rates.32 While the average disability, and economic
impact on average will be higher per individual with traumatic
spinal cord injury, given the high costs among even those with
less disability (e.g. for individuals with ASIA Impairment
Scale, Grade D, the lifetime cost per individual is estimated
to be £0.47million) this would suggest the direct care costs for
DCM are an underestimate.
Financial outcomes are almost never considered in DCM
research to date,13,14 and while a significant impact on unemployment is logical, to date, this has been poorly characterized.
As part of AO Spine RECODE-DCM,9 a core outcome set for
DCM research is being developed. This includes some consideration of financial impact, which should better serve these
analyses in the future.

Are Health-Economic Models Fully Generalizable?
Health economic analysis within DCM has so far relied on
aggregate data, and its extrapolation across subgroups may
represent a further knowledge gap.18 Here we contextualize
3 important potential areas of Socio-Economic Status (SES),
lower and middle vs. higher-income countries, and age,
although there are likely more.
SES broadly refers to an individual’s economic and social
circumstances and is typically assessed based on income, education, and/or occupation. The ONS (UK) uses occupation as
an overall surrogate.33 SES has been linked to a wide range of
health problems, driven by its interaction with key determinants of health: access to healthcare, environmental exposure,
and health behavior.34
Within DCM, there are indicators of inequalities in care,
albeit their impact is less certain. In a population study using
the US National Inpatient Sample (2001-2010), private insurance status and white ethnicity were among independent predictors for receiving an anterior versus posterior surgical
approach.35 Moreover, in their follow up study, the authors
also identified that private insurance status was an independent
predictor for receiving a multi-level (3þ) instrumented
fusion.36 Within the Myelopathy.org survey of people living
with DCM, diagnostic delay was greater among those of black
or African American ethnicity, with additional trends for those
with lower educational qualifications.6 In a recent evaluation of
patients undergoing ACDF (all indications) from a single US
center over 8 years (N ¼ 2387), state-funded (Medicare / Medicaid) patients had more co-morbidities, longer hospitalization,
and more frequently returned for reassessment within 90 days
than insurance funded patients.37 Taken together, this suggests
that SES is likely an important determining factor of treatment

6Davies et al

Global Spine Journal
127S

costs and outcomes as well as a potential sources of unconsciousness bias during the decision making process for the
individual’s treatment.
Of the health-economic data produced so far, surgery is
considered cost-effective across age groups.20-23 However, age
is recognized to impact DCM, associated with greater perioperative morbidity and a reduced, albeit still meaningful,
amount of recovery.38 It is noteworthy that while the subject
has received significant research attention, the majority of studied cohorts remain young (average ages 60 to 65), and it is not
certain whether this data is generalizable to higher age groups,
as increasingly seen in higher income countries.39 It is noteworthy that while a correlated surrogate, age is not necessarily
the same as frailty, and this distinction may further need to be
considered as this subgroup is addressed.40
The requirements in lower and middle income countries
[LMIC] will also be different.41 Firstly, the different population
demographics may have different epidemiology. Given the
lack of robust health surveillance, and reduced access to diagnostic imaging, experiences from non-traumatic spinal cord
injury (NTSCI) probably provide the only current estimates.
Considering the few studies completed, the prevalence of
degenerative spinal conditions remains high. For example, in
a systematic review (2017) of NTSCI studies from sub-Saharan
Africa, degenerative disorders accounted for 1.5-29% of cases.
However, only 3 of the 19 studies included had access to an
MRI scanner, with only 4-26% of patients receiving such a
scan.42 A study using MRI in Ghana found 75.9% of NTSCI
cases had degenerative disease of the spine.43 Secondly, management options may be influenced by the low-resource setting.41 For example, diagnostic imaging, such as MRI, may not
be available or may be too costly for patients or their families to
afford, and alternative diagnostic/treatment options sought.
Clinical follow-up is often a challenge to provide, given the
large distances patients may live from centers, and the poor
communications infrastructure. Furthermore, surgical techniques may have to be adapted—for example, spinal implants
are often not paid for by public health systems in LMIC, given
their often-significant cost. Despite these challenges, providers
are exploring alternatives; conventional myelography has been
demonstrated as a potentially safe and effective alternative for
selecting appropriate candidates for surgery in these settings44
while alternative, low cost, surgical implants are being sourced
from manufacturers in India, China, and South Korea.45 However, these factors will contribute to a different healtheconomic model.

health-economic argument for change, convincing healthcare
leaders and funders to focus their attention on this public health
priority will remain an uphill struggle. Notably these significant costs to the individual and society can be avoided, if DCM
can be diagnosed and treated in a timely manner.

Why Do We Need to Better Characterize
the Socio-Economic Impact?

ORCID iDs

Despite its prevalence and clinical relevance, DCM remains
under-recognized and under-treated. Increasing awareness has
been identified as the number one priority by AO Spine
RECODE-DCM [aospine.org/recode], fundamental to increasing diagnosis and timely treatment, but also much needed
research investment. However, without a strong and robust

Conclusions
The Socio-Economic impact of DCM is a critical knowledge
gap. Indicators, including the current best estimate from Myelo
pathy.org, suggest the cost of illness is substantial. By properly
determining and disseminating the information on the socioeconomic impact of DCM, one may anticipate a change in the
individual and societal value of investing in the care of patients
with DCM and in the research and innovation for DCM.
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